James D. Cavenagh

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

Hervé Dombret, John F. Seymour, Aleksandra Butrym et al. · Blood · 2015 · 1.1K citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +2

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

Régis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli et al. · New England Journal of Medicine · 2022 · 298 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without <i>NPM1</i> Mutations

Sylvie Freeman, Robert K. Hills, Paul Virgo et al. · Journal of Clinical Oncology · 2018 · 200 citations · Full text

Medicine, Hematology, Oncology +17

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

Jesús F. San Miguel, Paul G. Richardson, Pieter Sonneveld et al. · Leukemia · 2008 · 184 citations

Pharmacy, Nephrology, Pharmacotherapy +14

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel H. Russell, Amanda Gilkes et al. · Blood · 2016 · 146 citations · Full text

Medicine, Oncology, Pharmacology +11